Amgen (NASDAQ:AMGN) announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA&...
First Phase 3 PDT study in patients with sBCC in the United States. Rigorous dual endpoints requiring complete clinical and cytological clearance of m...
Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlan...
First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic ...
Dizal (, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that th...
Aileron Therapeutics, a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs i...
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis ...
Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), an innovative company in the field of precision onco...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and ten23 health, the human-centri...
Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale glo...
Hovione Farmaciência, S.A.(“HOVIONE”) and Zerion Pharma A/S (“ZERION”) today announced that they have expanded their part...
World-leading contract research organization (CRO) Sygnature Discovery is delighted to announce the appointment of Amira Modi as its new Chief Operating ...
In a year when metabolic diseases have drawn major investor interest, the newest player has big-name backing, a sizable war chest and veteran leadership. ...
Thryv Therapeutics, a clinical stage biotech company dedicated to developing treatments for rare and life-threatening cardiovascular indications, announced...
© 2026 Biopharma Boardroom. All Rights Reserved.
